Ameritas Investment Partners’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Ameritas Investment Partners’s Portfolio CBMG Stock Details CBMG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-958	Closed	-$18K	–	3102
2020 Q4	$18K	Hold	958	–	–	﹤0.01%	2544
2020 Q3	$18K	Hold	958	–	–	﹤0.01%	2452
2020 Q2	$14K	Hold	958	–	–	﹤0.01%	2564
2020 Q1	$15K	Hold	958	–	–	﹤0.01%	2356
2019 Q4	$16K	Hold	958	–	–	﹤0.01%	2532
2019 Q3	$14K	Hold	958	–	–	﹤0.01%	2594
2019 Q2	$16K	Hold	958	–	–	﹤0.01%	2599
2019 Q1	$17K	Hold	958	–	–	﹤0.01%	2479
2018 Q4	$17K	Hold	958	–	–	﹤0.01%	2449
2018 Q3	$17K	Hold	958	–	–	﹤0.01%	2603
2018 Q2	$19K	Buy	+958	New	+$17.9K	﹤0.01%	2554
2017 Q2	–	Sell	-759	Closed	-$9K	–	3083
2017 Q1	$9K	Buy	+759	New	+$9.22K	﹤0.01%	2746

Ameritas Investment Partners's CBMG Position: Q1 2021 in Review

Ameritas Investment Partners sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q1 2021, closing a stake of 958 shares — an estimated $18K sold.

Ameritas Investment Partners first reported a position in CBMG in Q1 2017 and held it in 12 quarters. The position peaked at $19K in Q2 2018. 0 funds tracked by Wall St. Rank hold CBMG as of Q1 2021.

Ameritas Investment Partners reported no remaining Cellular Biomedicine Group, Inc. position as of Q1 2021 after selling out during the quarter.
Ameritas Investment Partners sold 958 Cellular Biomedicine Group, Inc. shares in Q1 2021, an estimated $18K.
Ameritas Investment Partners first reported a position in Cellular Biomedicine Group, Inc. in Q1 2017 and held it in 12 quarters.
Ameritas Investment Partners's Cellular Biomedicine Group, Inc. position peaked at $19K in Q2 2018.
0 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q1 2021.

Based on Ameritas Investment Partners's 13F filing for Q1 2021, filed 14 May 2021.